Virtual Lymphoma Hub Satellite Symposium
During the virtual Lymphoma Hub Satellite Symposium, an international panel of 5 experts will provide an overview of the different treatment approaches for patients with relapsed/refractory disease.
While frontline treatment approaches in non-Hodgkin lymphomas and CLL have made tremendous progress, the treatment of patients with relapsed/refractory disease can be a challenge.
The clinical situation based on past treatment history and disease features are quite variable. Often, these patients present with characteristics that make the disease difficult to treat. Factors like chemo-resistance, exhausted bone marrow reserve or reduced performance status pose special challenges to physicians and require a very personalized approach to treatment strategy.
This overview will highlight the latest advances in the field, special treatment challenges and regional differences to help physicians make the best treatment decision possible for patients with relapsed/refractory disease in areas with a high unmet medical need.
How I treat relapsed/refractory disease – DLBCL and CLL
Sunday November 8, 2020 | 15:50 CET
Welcome and introductions
Q&A and round table discussion
Summary and conclusions